Moxifloxacin ophthalmic

Moxifloxacin ophthalmic is a prescription medication used to treat the symptoms of bacterial conjunctivitis. 

• Moxifloxacin ophthalmic is available under the following different brand names: Vigamox, Moxeza

Common side effects of Moxifloxacin ophthalmic include:

• dry eyes or watery eyes;
• eye pain or discomfort;
• blurred vision; or
• mild itching, redness, or other irritation.

Serious side effects of Moxifloxacin ophthalmic include:

• severe burning, stinging, or irritation after using this medicine; or
• eye swelling, redness, severe discomfort, crusting, or drainage (may be signs of infection).

Rare side effects of Moxifloxacin ophthalmic include:

• none 

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult and pediatric dosage

Ophthalmic solution

• 0.5%

Bacterial Conjunctivitis

Adult dosage

• Moxeza: 1 drop instilled into the affected eye(s) every 12 hours  for 1 week
• Vigamox: 1 drop instilled into the affected eye(s) every 8 hours for 1 week

Pediatric dosage

• Moxeza
  • Aged less than 4 months: Safety and efficacy not established
  • Aged above 4 months: 1 drop instilled into the affected eye(s) every 12 hour
• Vigamox
  • 1 drop instilled into the affected eye(s) every 8 hours for 1 week

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first

• Moxifloxacin ophthalmic has no noted severe interactions with any other drugs.
• Moxifloxacin ophthalmic has no noted serious interactions with any other drugs.
• Moxifloxacin ophthalmic has no noted moderate interactions with any other drugs.
• Moxifloxacin ophthalmic has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• Hypersensitivity to quinolones or other components of the formulation

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Moxifloxacin ophthalmic?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Moxifloxacin ophthalmic?”

Cautions

• May result in overgrowth of nonsusceptible organisms, including fungi
• Some patients may require slit-lamp biomicroscopy and fluorescein staining
• Not for subconjunctival injection
• Nor for intracameral use or injection; will cause damage to corneal endothelium if introduced directly into the anterior chamber of the eye
• Toxic anterior segment syndrome (TASS) is reported following intraocular administration of moxifloxacin; TASS is typically characterized by anterior chamber inflammatory reactions, such as fibrin, cell or flare, and corneal edema, but other events, such as hypopyon, keratic precipitates or vitreous opacities may also occur
• Contact lenses should not be worn during therapy

Pregnancy & Lactation

• There are no adequate and well-controlled studies on pregnant women to inform any drug-associated risks

Lactation

• There are no data regarding the presence of human milk, effects on breastfed infants, or milk production/excretion to inform risk to an infant during lactation
• A study in lactating rats has shown the transfer of drugs into milk following oral administration
• Systemic levels of moxifloxacin following topical ocular administration are low and not known whether measurable levels of moxifloxacin would be present in maternal milk following topical ocular administration
• Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from drug